Genmab — Juni 2019
-
https://www.marketscreener.com/news/BioNTech-and-Genmab-Initiate-First-In-Human-Phase-I-IIa-Trial-of-Bispecific-Antibody-DuoBody-PD-L1x--28765817/?utm_medium=RSS&utm_content=20190617 BioNTech and Genmab Initiate First-In-Human Phase I/IIa Trial of Bispecific Antibody DuoBody
-PD-L1x4-1BB in Solid Tumors -
Hvis man koncentrerer snakken, er det MAIA vi lige nu afventer. Og Stockbull har ret i at man ikke skal panikke. Genmab har præciseret at de venter det i Q2, og så kan de umuligt have et forecast der indregner mere end allerhøjst 6 mdr. for Maia. Højst sandsynligt 5 mdr. Så ok at sige klap lige hesten. Ansøgningen er kompliceret og RTOR kan tage lang tid, har vi set.
-
Hvornår kommer recept tal?
-
-
Ifølge Genmabs liste over archived events har der slet ikke været nogen siden JPM i starten af januar. Jeg har muligvis misset noget, så må lige spørge: hvorfra ved vi, at Genmab har deltaget i konferencer, som de ikke meddeler at have deltaget i? https://ir.genmab.com/events-and-presentations#tab2
-
-
-
tidligere var der live cast audio på dem alle, direkte fra Genmabs hjemmeside, var er mange, der har fulgt dem
-
vi var
-
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind